Table 3.
Risk factors studied for association with more severe hepatitis C virus recurrence
| Factor | Evidence |
| Donor | |
| Age > 40 yr | ↑↑↑ |
| Living donor | ↔ |
| Split liver | ↔ |
| DCD | ↔ |
| HCV+ | ↔ |
| Macrovesicular steatosis > 30% | ↑↓ |
| IRI | ↑↓ |
| IL28B “CC” genotype | ↑↓ |
| Virus | |
| HCV genotype 1 | ↑ |
| High pre-transplant HCV RNA | ↑ |
| HCV RNA 4 mo post LT ≥ 1 × 109 mEq/mL | ↑↑ |
| CMV viremia | ↑↑↑ |
| HIV coinfection | ↑↑ |
| Recipient | |
| Female sex | ↑↑ |
| African American D/R mismatch | ↑↑ |
| African American D/R match | ↔ |
| Metabolic syndrome1 | ↑ |
| IL28B non-“CC” genotype | ↑ |
| Immunosuppression | |
| Pulsed corticosteroids for American College of Rheumatology | ↑↑↑ |
| Tacrolimus (vs CsA) | ↑↓ |
| Sirolimus | ↑ |
| Thymoglobulin | ↔ |
| Basiliximab | ↔ |
| OKT3 | ↑ |
1
Metabolic syndrome defined by ATP-III criteria 1 yr post liver transplantation (LT)[37], homeostasis model assessment-estimated insulin resistance > 2.5 4 mo post LT[46], or hepatic steatosis ≥ 5% on an index liver allograft biopsy 1 yr post-LT[47]. ↑: Evidence of increased risk; ↔: Evidence of no increased risk; ↑↓: Indeterminate risk; DCD: Donation after cardiac death; HCV: Hepatitis C virus; CMV: Cytomegalovirus; HIV: Human immunodeficiency virus; CsA: Cyclosporin A; OKT3: Muromonab-CD3; IRI: Ischemia reperfusion injury.